Why the study?
Cardiovascular toxicity is a common complication of cancer treatment that impacts long-term survival, but scientific evidence regarding the management of these complications in cancer patients remains scarce.
Answers are grounded in this paper and cite their sources.
These guidelines establish a standardized, multidisciplinary approach to mitigating cardiovascular toxicity in cancer patients, emphasizing early detection and management to prevent long-term cardiac complications.
One of the most common side effects of cancer treatment is cardiovascular disease, which substantially impacts long-term survivor's prognosis. Cardiotoxicity can be related with either a direct side effect of antitumor therapies or an accelerated development of cardiovascular diseases in the presence of preexisting risk factors. Even though it is widely recognized as an alarming clinical problem, scientific evidence is scarce in the management of these complications in cancer patients. Consequently, current recommendations are based on expert consensus. This Guideline represents SEOM's ongoing commitment to progressing and improving supportive care for cancer patients.
No takes yet. Share an insight, caveat, or question.
Santaballa et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: